Received Dec 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
The patient fainted after GARDASIL 9 administration.; This Spontaneous report was received from Merck employee and referred to a male patient of unknown age. The patient's medical history included Fainting. The patient's previous drug reactions or allergies, and concomitant medications were not reported. On an unknown date, patient was vaccinated with GARDASIL 9 at a dose of 0.50 mL for prophylaxis (strength, route of administration, anatomical location, lot number, and expiration date were not reported). On an unspecified date (reported as after GARDASIL 9 administration), the patient fainted. AT the time of the report outcome fainted was not provided. The causality assessment between the event fainted to Human Papillomavirus 9-valent Vaccine, Recombinant Suspension for injection was not reported. Upon internal review, the event fainted was considered to be other medically important condition.
Medical History/Concurrent Conditions: Fainting